Figure 1

Receptors and ion channels that may mediate phytocannabinoid effects on seizures and epilepsy are reviewed. Endocannabinoid system components including CB1 and CB2 receptors are central to the discussion.

Figure 2

TRPV1 channel modulation by phytocannabinoids is explored as a potential anti-seizure mechanism. Cannabidiol and other plant-derived cannabinoids interact with transient receptor potential channels.

Figure 3

GPR55 receptor signaling and its modulation by phytocannabinoids are examined in the context of seizure susceptibility. Antagonism of this receptor may contribute to the anticonvulsant properties of CBD.

Figure 4

Serotonin receptor interactions with phytocannabinoids, particularly 5-HT1A agonism by cannabidiol, are discussed as a mechanism underlying anti-epileptic effects. Serotonergic modulation may reduce seizure threshold.

Figure 5

Sodium channel blockade by phytocannabinoids represents a direct mechanism for reducing neuronal hyperexcitability. Cannabidiol's interaction with voltage-gated sodium channels is particularly relevant to seizure control.

Figure 6

Calcium channel modulation by plant cannabinoids may contribute to synaptic transmission regulation. Reduced calcium influx at presynaptic terminals could decrease excitatory neurotransmitter release.

Figure 7

GABAergic system interactions with phytocannabinoids are examined, including positive allosteric modulation of GABA-A receptors. Enhanced inhibitory neurotransmission represents a key anti-seizure mechanism.

Figure 8

Glutamate receptor modulation by phytocannabinoids may reduce excitotoxicity associated with seizure activity. NMDA and AMPA receptor interactions are discussed in the context of neuroprotection.

Figure 9

Adenosine signaling enhancement by cannabidiol through equilibrative nucleoside transporter inhibition is explored. Increased extracellular adenosine may contribute to seizure suppression and neuroprotection.

Figure 10

PPARgamma receptor activation by phytocannabinoids is examined for anti-inflammatory and neuroprotective effects in epilepsy. Nuclear receptor signaling may modulate neuroinflammation-driven seizure susceptibility.

Figure 11

Glycine receptor potentiation by cannabinoids is discussed as an additional inhibitory mechanism. Enhanced glycinergic transmission may complement GABAergic effects in seizure control.

Figure 12

Opioid receptor interactions with phytocannabinoids are explored for potential synergistic anti-epileptic effects. Cross-talk between endocannabinoid and endogenous opioid systems may influence seizure networks.

Figure 13

Potassium channel modulation by phytocannabinoids represents a mechanism for regulating neuronal repolarization. Enhanced potassium conductance may stabilize membrane potential and reduce seizure vulnerability.

Figure 14

Mitochondrial targets of phytocannabinoids in epilepsy are examined, including effects on the mitochondrial permeability transition pore. Mitochondrial stabilization may protect neurons during prolonged seizure activity.

Figure 15

TRPA1 channel interactions with phytocannabinoids are discussed in the context of neuronal excitability modulation. This TRP channel subtype may contribute to cannabinoid-mediated effects on sensory and seizure networks.

Figure 16

Endocannabinoid system tone and its relationship to seizure threshold are illustrated. Deficient endocannabinoid signaling may lower seizure resistance, supporting exogenous phytocannabinoid supplementation.

Figure 17

Clinical evidence for cannabidiol in treatment-resistant epilepsy syndromes including Dravet and Lennox-Gastaut is summarized. FDA-approved formulations have demonstrated significant seizure frequency reduction.

Figure 18

Cannabigerol and other minor phytocannabinoids are assessed for anti-seizure potential. Preclinical evidence suggests these less-studied compounds may offer complementary mechanisms to cannabidiol.

Figure 19

THC and THCV effects on seizure models demonstrate dual pro- and anticonvulsant properties depending on dose and model type. Low-dose THC may provide seizure protection while higher doses increase risk.

Figure 20

Pharmacokinetic considerations for phytocannabinoids in epilepsy management include bioavailability, metabolism, and drug-drug interactions. CYP450 interactions with antiepileptic drugs require clinical monitoring.

Figure 21

Multi-target receptor engagement by individual phytocannabinoids is mapped, showing how single compounds interact with multiple receptors simultaneously. This polypharmacology may underlie the broad-spectrum anti-seizure effects.

Figure 22

Neuroinflammatory pathways modulated by phytocannabinoids in epilepsy include microglial polarization, cytokine release, and blood-brain barrier integrity. Anti-inflammatory effects may reduce seizure-induced brain damage.

Figure 23

Synaptic plasticity changes induced by phytocannabinoids may influence long-term seizure susceptibility. Modulation of long-term potentiation and depression at excitatory synapses is discussed.

Figure 24

Dose-response relationships for cannabidiol in seizure models illustrate optimal therapeutic windows. Inverted U-shaped dose-response curves are observed in some preclinical paradigms.

Figure 25

Astrocyte interactions with phytocannabinoids in epilepsy highlight glial contributions to seizure modulation. CB1 receptors on astrocytes influence glutamate uptake and synaptic transmission.

Figure 26

Entourage effect considerations for phytocannabinoid-based epilepsy therapy suggest whole-plant extracts may provide enhanced efficacy over isolated compounds. Terpenes and minor cannabinoids may modulate primary effects.

Figure 27

Pediatric epilepsy syndrome-specific responses to phytocannabinoids are reviewed. Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex show varying degrees of cannabidiol responsiveness.

Figure 28

Adult focal epilepsy responses to phytocannabinoid therapy are examined from available clinical data. Adjunctive cannabidiol reduces seizure frequency in treatment-resistant focal epilepsy patients.

Figure 29

Safety profiles of phytocannabinoids in epilepsy patients are reviewed, including hepatotoxicity risk with concurrent valproate use. Somnolence and decreased appetite are common adverse effects.

Figure 30

Emerging phytocannabinoid formulations for epilepsy include transdermal, intranasal, and sublingual delivery systems. Alternative routes of administration may improve bioavailability and reduce gastrointestinal side effects.

Figure 31

Genetic factors influencing individual responses to phytocannabinoid therapy in epilepsy are explored. Polymorphisms in cannabinoid receptors and metabolizing enzymes may predict treatment outcomes.

Figure 32

Electroencephalographic changes associated with phytocannabinoid treatment in epilepsy patients reflect underlying neurophysiological modulation. Reduced interictal epileptiform discharges indicate improved cortical stability.

Figure 33

Animal models of epilepsy used to study phytocannabinoid mechanisms are catalogued, spanning acute seizure models and chronic epilepsy paradigms. Model-specific responses inform translational relevance.

Figure 34

Future research directions for phytocannabinoids in epilepsy include biomarker-guided therapy, combination strategies with conventional antiepileptics, and investigation of novel minor cannabinoids with anti-seizure potential.

Figure 35

Molecular architecture of the CB1 cannabinoid receptor, a key mediator of phytocannabinoid effects in the central nervous system. CB1 receptors are among the most abundant G-protein coupled receptors in the brain and are implicated in seizure modulation.

Figure 36

Structural representation of CB1 receptor binding domains relevant to phytocannabinoid interactions. The CB1 receptor's widespread expression in cortical and hippocampal regions suggests a significant role in epilepsy pathophysiology.

Figure 37

Signaling cascade downstream of CB1 receptor activation by phytocannabinoids. Activation of CB1 receptors is associated with modulation of neurotransmitter release, which may influence seizure threshold.

Figure 38

Ligand-receptor interaction model for CB1 and select phytocannabinoid compounds. Understanding these binding characteristics is essential for developing cannabinoid-based antiepileptic strategies.

Figure 39

Schematic of CB1 receptor distribution across brain regions implicated in epileptogenesis. Regional differences in CB1 expression may account for variable antiseizure efficacy of different phytocannabinoids.

Figure 40

Molecular architecture of the CB1 cannabinoid receptor, a key mediator of phytocannabinoid effects in the central nervous system. CB1 receptors are among the most abundant G-protein coupled receptors in the brain and are implicated in seizure modulation.

Figure 41

Structural representation of CB1 receptor binding domains relevant to phytocannabinoid interactions. The CB1 receptor's widespread expression in cortical and hippocampal regions suggests a significant role in epilepsy pathophysiology.

Figure 42

Signaling cascade downstream of CB1 receptor activation by phytocannabinoids. Activation of CB1 receptors is associated with modulation of neurotransmitter release, which may influence seizure threshold.

Figure 43

Ligand-receptor interaction model for CB1 and select phytocannabinoid compounds. Understanding these binding characteristics is essential for developing cannabinoid-based antiepileptic strategies.

Figure 44

Schematic of CB1 receptor distribution across brain regions implicated in epileptogenesis. Regional differences in CB1 expression may account for variable antiseizure efficacy of different phytocannabinoids.

Figure 45

Molecular architecture of the CB1 cannabinoid receptor, a key mediator of phytocannabinoid effects in the central nervous system. CB1 receptors are among the most abundant G-protein coupled receptors in the brain and are implicated in seizure modulation.

Figure 46

Structural representation of CB1 receptor binding domains relevant to phytocannabinoid interactions. The CB1 receptor's widespread expression in cortical and hippocampal regions suggests a significant role in epilepsy pathophysiology.

Figure 47

Signaling cascade downstream of CB1 receptor activation by phytocannabinoids. Activation of CB1 receptors is associated with modulation of neurotransmitter release, which may influence seizure threshold.

Figure 48

Ligand-receptor interaction model for CB1 and select phytocannabinoid compounds. Understanding these binding characteristics is essential for developing cannabinoid-based antiepileptic strategies.

Figure 49

Schematic of CB1 receptor distribution across brain regions implicated in epileptogenesis. Regional differences in CB1 expression may account for variable antiseizure efficacy of different phytocannabinoids.

Figure 50

Molecular architecture of the CB1 cannabinoid receptor, a key mediator of phytocannabinoid effects in the central nervous system. CB1 receptors are among the most abundant G-protein coupled receptors in the brain and are implicated in seizure modulation.

Figure 51

Structural overview of the CB2 cannabinoid receptor, which is primarily expressed in immune cells and microglia. CB2 activation by phytocannabinoids may modulate neuroinflammation associated with epilepsy.

Figure 52

Binding site topology of the CB2 receptor with phytocannabinoid ligands. Unlike CB1, CB2 receptors are associated more with peripheral immune modulation than direct neuronal signaling.

Figure 53

Downstream signaling pathways triggered by CB2 receptor engagement. Anti-inflammatory effects mediated through CB2 may contribute to neuroprotection in chronic epilepsy models.

Figure 54

Comparative structural analysis of CB1 and CB2 receptor binding pockets. Selectivity differences between these receptor subtypes influence the therapeutic profile of individual phytocannabinoids.

Figure 55

Expression pattern of CB2 receptors in neural tissue under inflammatory conditions. Upregulation of CB2 in activated microglia suggests a role in seizure-associated neuroinflammation.

Figure 56

Structural overview of the CB2 cannabinoid receptor, which is primarily expressed in immune cells and microglia. CB2 activation by phytocannabinoids may modulate neuroinflammation associated with epilepsy.

Figure 57

Binding site topology of the CB2 receptor with phytocannabinoid ligands. Unlike CB1, CB2 receptors are associated more with peripheral immune modulation than direct neuronal signaling.

Figure 58

Downstream signaling pathways triggered by CB2 receptor engagement. Anti-inflammatory effects mediated through CB2 may contribute to neuroprotection in chronic epilepsy models.

Figure 59

Comparative structural analysis of CB1 and CB2 receptor binding pockets. Selectivity differences between these receptor subtypes influence the therapeutic profile of individual phytocannabinoids.

Figure 60

Expression pattern of CB2 receptors in neural tissue under inflammatory conditions. Upregulation of CB2 in activated microglia suggests a role in seizure-associated neuroinflammation.

Figure 61

Structural overview of the CB2 cannabinoid receptor, which is primarily expressed in immune cells and microglia. CB2 activation by phytocannabinoids may modulate neuroinflammation associated with epilepsy.

Figure 62

Binding site topology of the CB2 receptor with phytocannabinoid ligands. Unlike CB1, CB2 receptors are associated more with peripheral immune modulation than direct neuronal signaling.

Figure 63

Downstream signaling pathways triggered by CB2 receptor engagement. Anti-inflammatory effects mediated through CB2 may contribute to neuroprotection in chronic epilepsy models.

Figure 64

Comparative structural analysis of CB1 and CB2 receptor binding pockets. Selectivity differences between these receptor subtypes influence the therapeutic profile of individual phytocannabinoids.

Figure 65

Expression pattern of CB2 receptors in neural tissue under inflammatory conditions. Upregulation of CB2 in activated microglia suggests a role in seizure-associated neuroinflammation.

Figure 66

Structural model of the GPR55 receptor, an orphan G-protein coupled receptor that responds to certain phytocannabinoids. GPR55 activation has been linked to changes in intracellular calcium signaling relevant to neuronal excitability.

Figure 67

Signaling pathway diagram for GPR55-mediated effects on neuronal function. Lysophosphatidylinositol and select cannabinoids activate GPR55, potentially influencing seizure susceptibility.

Figure 68

Molecular representation of GPR18 receptor interactions with phytocannabinoid compounds. GPR18 is expressed in brain tissue and may contribute to the complex pharmacology of cannabis-derived antiepileptic effects.

Figure 69

Comparative binding analysis of phytocannabinoids at GPR55 versus classical cannabinoid receptors. The distinct signaling profile of GPR55 suggests non-overlapping mechanisms of seizure modulation.

Figure 70

Downstream effector pathways of GPR55 and GPR18 activation in neural tissue. These orphan receptors represent emerging targets for understanding how phytocannabinoids modulate excitability beyond CB1/CB2.

Figure 71

Structural model of the GPR55 receptor, an orphan G-protein coupled receptor that responds to certain phytocannabinoids. GPR55 activation has been linked to changes in intracellular calcium signaling relevant to neuronal excitability.

Figure 72

Signaling pathway diagram for GPR55-mediated effects on neuronal function. Lysophosphatidylinositol and select cannabinoids activate GPR55, potentially influencing seizure susceptibility.

Figure 73

Molecular representation of GPR18 receptor interactions with phytocannabinoid compounds. GPR18 is expressed in brain tissue and may contribute to the complex pharmacology of cannabis-derived antiepileptic effects.

Figure 74

Comparative binding analysis of phytocannabinoids at GPR55 versus classical cannabinoid receptors. The distinct signaling profile of GPR55 suggests non-overlapping mechanisms of seizure modulation.

Figure 75

Downstream effector pathways of GPR55 and GPR18 activation in neural tissue. These orphan receptors represent emerging targets for understanding how phytocannabinoids modulate excitability beyond CB1/CB2.

Figure 76

Structural model of the GPR55 receptor, an orphan G-protein coupled receptor that responds to certain phytocannabinoids. GPR55 activation has been linked to changes in intracellular calcium signaling relevant to neuronal excitability.

Figure 77

Signaling pathway diagram for GPR55-mediated effects on neuronal function. Lysophosphatidylinositol and select cannabinoids activate GPR55, potentially influencing seizure susceptibility.

Figure 78

Molecular representation of GPR18 receptor interactions with phytocannabinoid compounds. GPR18 is expressed in brain tissue and may contribute to the complex pharmacology of cannabis-derived antiepileptic effects.

Figure 79

Comparative binding analysis of phytocannabinoids at GPR55 versus classical cannabinoid receptors. The distinct signaling profile of GPR55 suggests non-overlapping mechanisms of seizure modulation.

Figure 80

Downstream effector pathways of GPR55 and GPR18 activation in neural tissue. These orphan receptors represent emerging targets for understanding how phytocannabinoids modulate excitability beyond CB1/CB2.

Figure 81

Ion channel architecture of TRPV1 (transient receptor potential vanilloid 1), a non-selective cation channel activated by several phytocannabinoids. TRPV1 desensitization is associated with reduced neuronal hyperexcitability.

Figure 82

Structural model of TRPV1 channel pore domain and phytocannabinoid binding sites. Cannabidiol and other phytocannabinoids may exert antiepileptic effects through TRPV1 activation followed by desensitization.

Figure 83

TRPV2 channel structure and its interaction with phytocannabinoid agonists. TRPV2 is expressed in hippocampal neurons and may participate in regulating seizure threshold.

Figure 84

Calcium flux dynamics through TRPV channels upon phytocannabinoid stimulation. Initial channel activation followed by desensitization could reduce the sustained calcium influx that drives seizure propagation.

Figure 85

Comparative gating mechanisms of TRPV1 and TRPV2 in response to different phytocannabinoid concentrations. Dose-dependent effects on these channels may explain the biphasic activity observed in some epilepsy models.

Figure 86

Ion channel architecture of TRPV1 (transient receptor potential vanilloid 1), a non-selective cation channel activated by several phytocannabinoids. TRPV1 desensitization is associated with reduced neuronal hyperexcitability.

Figure 87

Structural model of TRPV1 channel pore domain and phytocannabinoid binding sites. Cannabidiol and other phytocannabinoids may exert antiepileptic effects through TRPV1 activation followed by desensitization.

Figure 88

TRPV2 channel structure and its interaction with phytocannabinoid agonists. TRPV2 is expressed in hippocampal neurons and may participate in regulating seizure threshold.

Figure 89

Calcium flux dynamics through TRPV channels upon phytocannabinoid stimulation. Initial channel activation followed by desensitization could reduce the sustained calcium influx that drives seizure propagation.

Figure 90

Comparative gating mechanisms of TRPV1 and TRPV2 in response to different phytocannabinoid concentrations. Dose-dependent effects on these channels may explain the biphasic activity observed in some epilepsy models.

Figure 91

Ion channel architecture of TRPV1 (transient receptor potential vanilloid 1), a non-selective cation channel activated by several phytocannabinoids. TRPV1 desensitization is associated with reduced neuronal hyperexcitability.

Figure 92

Structural model of TRPV1 channel pore domain and phytocannabinoid binding sites. Cannabidiol and other phytocannabinoids may exert antiepileptic effects through TRPV1 activation followed by desensitization.

Figure 93

TRPV2 channel structure and its interaction with phytocannabinoid agonists. TRPV2 is expressed in hippocampal neurons and may participate in regulating seizure threshold.

Figure 94

Calcium flux dynamics through TRPV channels upon phytocannabinoid stimulation. Initial channel activation followed by desensitization could reduce the sustained calcium influx that drives seizure propagation.

Figure 95

Comparative gating mechanisms of TRPV1 and TRPV2 in response to different phytocannabinoid concentrations. Dose-dependent effects on these channels may explain the biphasic activity observed in some epilepsy models.

Figure 96

Ion channel architecture of TRPV1 (transient receptor potential vanilloid 1), a non-selective cation channel activated by several phytocannabinoids. TRPV1 desensitization is associated with reduced neuronal hyperexcitability.

Figure 97

Structural model of TRPV1 channel pore domain and phytocannabinoid binding sites. Cannabidiol and other phytocannabinoids may exert antiepileptic effects through TRPV1 activation followed by desensitization.

Figure 98

TRPV2 channel structure and its interaction with phytocannabinoid agonists. TRPV2 is expressed in hippocampal neurons and may participate in regulating seizure threshold.

Figure 99

Calcium flux dynamics through TRPV channels upon phytocannabinoid stimulation. Initial channel activation followed by desensitization could reduce the sustained calcium influx that drives seizure propagation.

Figure 100

Comparative gating mechanisms of TRPV1 and TRPV2 in response to different phytocannabinoid concentrations. Dose-dependent effects on these channels may explain the biphasic activity observed in some epilepsy models.

Figure 101

Structural representation of the TRPA1 (transient receptor potential ankyrin 1) channel, which responds to several plant-derived cannabinoids. TRPA1 modulation may influence nociceptive and seizure-related pathways.

Figure 102

TRPM8 channel architecture and its sensitivity to phytocannabinoid compounds. As a cold-sensing ion channel expressed in certain brain regions, TRPM8 represents an unconventional target for seizure modulation.

Figure 103

Ligand interaction model showing phytocannabinoid binding at the TRPA1 channel. Activation and subsequent desensitization of TRPA1 may contribute to the overall antiepileptic profile of cannabis extracts.

Figure 104

Signaling outcomes of TRPA1 and TRPM8 channel modulation in neuronal tissue. These TRP channels add complexity to the multi-target pharmacology of phytocannabinoids in epilepsy.

Figure 105

Comparative selectivity profile of major phytocannabinoids across TRP channel subtypes. Differential potency at TRPV1, TRPA1, and TRPM8 may determine the net effect on neuronal excitability.

Figure 106

Structural representation of the TRPA1 (transient receptor potential ankyrin 1) channel, which responds to several plant-derived cannabinoids. TRPA1 modulation may influence nociceptive and seizure-related pathways.

Figure 107

TRPM8 channel architecture and its sensitivity to phytocannabinoid compounds. As a cold-sensing ion channel expressed in certain brain regions, TRPM8 represents an unconventional target for seizure modulation.

Figure 108

Ligand interaction model showing phytocannabinoid binding at the TRPA1 channel. Activation and subsequent desensitization of TRPA1 may contribute to the overall antiepileptic profile of cannabis extracts.

Figure 109

Signaling outcomes of TRPA1 and TRPM8 channel modulation in neuronal tissue. These TRP channels add complexity to the multi-target pharmacology of phytocannabinoids in epilepsy.

Figure 110

Comparative selectivity profile of major phytocannabinoids across TRP channel subtypes. Differential potency at TRPV1, TRPA1, and TRPM8 may determine the net effect on neuronal excitability.

Figure 111

Structural representation of the TRPA1 (transient receptor potential ankyrin 1) channel, which responds to several plant-derived cannabinoids. TRPA1 modulation may influence nociceptive and seizure-related pathways.

Figure 112

TRPM8 channel architecture and its sensitivity to phytocannabinoid compounds. As a cold-sensing ion channel expressed in certain brain regions, TRPM8 represents an unconventional target for seizure modulation.

Figure 113

Ligand interaction model showing phytocannabinoid binding at the TRPA1 channel. Activation and subsequent desensitization of TRPA1 may contribute to the overall antiepileptic profile of cannabis extracts.

Figure 114

Signaling outcomes of TRPA1 and TRPM8 channel modulation in neuronal tissue. These TRP channels add complexity to the multi-target pharmacology of phytocannabinoids in epilepsy.

Figure 115

Comparative selectivity profile of major phytocannabinoids across TRP channel subtypes. Differential potency at TRPV1, TRPA1, and TRPM8 may determine the net effect on neuronal excitability.

Figure 116

Pentameric structure of the glycine receptor, an inhibitory ligand-gated ion channel modulated by certain phytocannabinoids. Enhanced glycinergic inhibition could contribute to seizure suppression.

Figure 117

GABA-A receptor complex and phytocannabinoid interaction sites. GABA-A receptors are the primary mediators of fast inhibitory neurotransmission, and their positive modulation is a well-established antiepileptic mechanism.

Figure 118

Subunit composition of GABA-A receptors relevant to phytocannabinoid sensitivity. Specific subunit combinations (particularly those containing alpha and delta subunits) may be preferentially modulated by cannabidiol.

Figure 119

Chloride conductance changes mediated by phytocannabinoid enhancement of glycine receptor function. Increased inhibitory tone through glycine receptors may synergize with GABAergic mechanisms to reduce seizure activity.

Figure 120

Allosteric modulation sites on the GABA-A receptor for phytocannabinoid binding. These sites are distinct from benzodiazepine and barbiturate binding pockets, suggesting a unique mechanism of action.

Figure 121

Pentameric structure of the glycine receptor, an inhibitory ligand-gated ion channel modulated by certain phytocannabinoids. Enhanced glycinergic inhibition could contribute to seizure suppression.

Figure 122

GABA-A receptor complex and phytocannabinoid interaction sites. GABA-A receptors are the primary mediators of fast inhibitory neurotransmission, and their positive modulation is a well-established antiepileptic mechanism.

Figure 123

Subunit composition of GABA-A receptors relevant to phytocannabinoid sensitivity. Specific subunit combinations (particularly those containing alpha and delta subunits) may be preferentially modulated by cannabidiol.

Figure 124

Chloride conductance changes mediated by phytocannabinoid enhancement of glycine receptor function. Increased inhibitory tone through glycine receptors may synergize with GABAergic mechanisms to reduce seizure activity.

Figure 125

Allosteric modulation sites on the GABA-A receptor for phytocannabinoid binding. These sites are distinct from benzodiazepine and barbiturate binding pockets, suggesting a unique mechanism of action.

Figure 126

Pentameric structure of the glycine receptor, an inhibitory ligand-gated ion channel modulated by certain phytocannabinoids. Enhanced glycinergic inhibition could contribute to seizure suppression.

Figure 127

GABA-A receptor complex and phytocannabinoid interaction sites. GABA-A receptors are the primary mediators of fast inhibitory neurotransmission, and their positive modulation is a well-established antiepileptic mechanism.

Figure 128

Subunit composition of GABA-A receptors relevant to phytocannabinoid sensitivity. Specific subunit combinations (particularly those containing alpha and delta subunits) may be preferentially modulated by cannabidiol.

Figure 129

Chloride conductance changes mediated by phytocannabinoid enhancement of glycine receptor function. Increased inhibitory tone through glycine receptors may synergize with GABAergic mechanisms to reduce seizure activity.

Figure 130

Allosteric modulation sites on the GABA-A receptor for phytocannabinoid binding. These sites are distinct from benzodiazepine and barbiturate binding pockets, suggesting a unique mechanism of action.

Figure 131

Pentameric structure of the glycine receptor, an inhibitory ligand-gated ion channel modulated by certain phytocannabinoids. Enhanced glycinergic inhibition could contribute to seizure suppression.

Figure 132

GABA-A receptor complex and phytocannabinoid interaction sites. GABA-A receptors are the primary mediators of fast inhibitory neurotransmission, and their positive modulation is a well-established antiepileptic mechanism.

Figure 133

Subunit composition of GABA-A receptors relevant to phytocannabinoid sensitivity. Specific subunit combinations (particularly those containing alpha and delta subunits) may be preferentially modulated by cannabidiol.

Figure 134

Chloride conductance changes mediated by phytocannabinoid enhancement of glycine receptor function. Increased inhibitory tone through glycine receptors may synergize with GABAergic mechanisms to reduce seizure activity.

Figure 135

Allosteric modulation sites on the GABA-A receptor for phytocannabinoid binding. These sites are distinct from benzodiazepine and barbiturate binding pockets, suggesting a unique mechanism of action.

Figure 136

Structural model of the 5-HT1A receptor, a serotonin receptor subtype activated by cannabidiol. 5-HT1A agonism is associated with anxiolytic and potential antiseizure properties.

Figure 137

Binding pocket analysis of 5-HT receptor subtypes for phytocannabinoid compounds. Serotonergic modulation represents an important non-endocannabinoid mechanism for cannabidiol's anticonvulsant activity.

Figure 138

Downstream signaling cascade following 5-HT1A receptor activation by cannabidiol. Activation of this receptor subtype is linked to reduced neuronal firing rates in limbic structures associated with epilepsy.

Figure 139

Distribution of 5-HT receptor subtypes in brain regions involved in seizure generation. The high density of 5-HT1A receptors in the hippocampus aligns with cannabidiol's observed efficacy in temporal lobe epilepsy models.

Figure 140

Comparative affinity of major phytocannabinoids at serotonin receptor subtypes. Cannabidiol shows notable 5-HT1A agonist activity, while other phytocannabinoids display distinct serotonergic profiles.

Figure 141

Structural model of the 5-HT1A receptor, a serotonin receptor subtype activated by cannabidiol. 5-HT1A agonism is associated with anxiolytic and potential antiseizure properties.

Figure 142

Binding pocket analysis of 5-HT receptor subtypes for phytocannabinoid compounds. Serotonergic modulation represents an important non-endocannabinoid mechanism for cannabidiol's anticonvulsant activity.

Figure 143

Downstream signaling cascade following 5-HT1A receptor activation by cannabidiol. Activation of this receptor subtype is linked to reduced neuronal firing rates in limbic structures associated with epilepsy.

Figure 144

Distribution of 5-HT receptor subtypes in brain regions involved in seizure generation. The high density of 5-HT1A receptors in the hippocampus aligns with cannabidiol's observed efficacy in temporal lobe epilepsy models.

Figure 145

Comparative affinity of major phytocannabinoids at serotonin receptor subtypes. Cannabidiol shows notable 5-HT1A agonist activity, while other phytocannabinoids display distinct serotonergic profiles.

Figure 146

Structural model of the 5-HT1A receptor, a serotonin receptor subtype activated by cannabidiol. 5-HT1A agonism is associated with anxiolytic and potential antiseizure properties.

Figure 147

Binding pocket analysis of 5-HT receptor subtypes for phytocannabinoid compounds. Serotonergic modulation represents an important non-endocannabinoid mechanism for cannabidiol's anticonvulsant activity.

Figure 148

Downstream signaling cascade following 5-HT1A receptor activation by cannabidiol. Activation of this receptor subtype is linked to reduced neuronal firing rates in limbic structures associated with epilepsy.

Figure 149

Distribution of 5-HT receptor subtypes in brain regions involved in seizure generation. The high density of 5-HT1A receptors in the hippocampus aligns with cannabidiol's observed efficacy in temporal lobe epilepsy models.

Figure 150

Comparative affinity of major phytocannabinoids at serotonin receptor subtypes. Cannabidiol shows notable 5-HT1A agonist activity, while other phytocannabinoids display distinct serotonergic profiles.

Figure 151

Structural model of the 5-HT1A receptor, a serotonin receptor subtype activated by cannabidiol. 5-HT1A agonism is associated with anxiolytic and potential antiseizure properties.

Figure 152

Binding pocket analysis of 5-HT receptor subtypes for phytocannabinoid compounds. Serotonergic modulation represents an important non-endocannabinoid mechanism for cannabidiol's anticonvulsant activity.

Figure 153

Downstream signaling cascade following 5-HT1A receptor activation by cannabidiol. Activation of this receptor subtype is linked to reduced neuronal firing rates in limbic structures associated with epilepsy.

Figure 154

Distribution of 5-HT receptor subtypes in brain regions involved in seizure generation. The high density of 5-HT1A receptors in the hippocampus aligns with cannabidiol's observed efficacy in temporal lobe epilepsy models.

Figure 155

Comparative affinity of major phytocannabinoids at serotonin receptor subtypes. Cannabidiol shows notable 5-HT1A agonist activity, while other phytocannabinoids display distinct serotonergic profiles.

Figure 156

Structural illustration of mu-opioid receptor interactions with phytocannabinoid compounds. Cross-talk between the endocannabinoid and opioid systems may influence seizure threshold and post-ictal recovery.

Figure 157

Adenosine A1 receptor model and its modulation by cannabidiol through equilibrative nucleoside transporter inhibition. Enhanced adenosine signaling is associated with seizure termination and neuroprotection.

Figure 158

Signaling pathway integration between opioid and cannabinoid receptor systems in epilepsy. Bidirectional modulation between these systems suggests complex pharmacological interactions.

Figure 159

Adenosine A2A receptor structure and potential indirect modulation by phytocannabinoids. A2A receptors in the striatum and hippocampus may contribute to network-level effects on seizure propagation.

Figure 160

Receptor occupancy model for phytocannabinoids at opioid receptor subtypes. While direct binding affinity is modest, functional interactions between the two systems appear to be physiologically relevant.

Figure 161

Structural illustration of mu-opioid receptor interactions with phytocannabinoid compounds. Cross-talk between the endocannabinoid and opioid systems may influence seizure threshold and post-ictal recovery.

Figure 162

Adenosine A1 receptor model and its modulation by cannabidiol through equilibrative nucleoside transporter inhibition. Enhanced adenosine signaling is associated with seizure termination and neuroprotection.

Figure 163

Signaling pathway integration between opioid and cannabinoid receptor systems in epilepsy. Bidirectional modulation between these systems suggests complex pharmacological interactions.

Figure 164

Adenosine A2A receptor structure and potential indirect modulation by phytocannabinoids. A2A receptors in the striatum and hippocampus may contribute to network-level effects on seizure propagation.

Figure 165

Receptor occupancy model for phytocannabinoids at opioid receptor subtypes. While direct binding affinity is modest, functional interactions between the two systems appear to be physiologically relevant.

Figure 166

Structural illustration of mu-opioid receptor interactions with phytocannabinoid compounds. Cross-talk between the endocannabinoid and opioid systems may influence seizure threshold and post-ictal recovery.

Figure 167

Adenosine A1 receptor model and its modulation by cannabidiol through equilibrative nucleoside transporter inhibition. Enhanced adenosine signaling is associated with seizure termination and neuroprotection.

Figure 168

Signaling pathway integration between opioid and cannabinoid receptor systems in epilepsy. Bidirectional modulation between these systems suggests complex pharmacological interactions.

Figure 169

Adenosine A2A receptor structure and potential indirect modulation by phytocannabinoids. A2A receptors in the striatum and hippocampus may contribute to network-level effects on seizure propagation.

Figure 170

Receptor occupancy model for phytocannabinoids at opioid receptor subtypes. While direct binding affinity is modest, functional interactions between the two systems appear to be physiologically relevant.

Figure 171

Structural illustration of mu-opioid receptor interactions with phytocannabinoid compounds. Cross-talk between the endocannabinoid and opioid systems may influence seizure threshold and post-ictal recovery.

Figure 172

Adenosine A1 receptor model and its modulation by cannabidiol through equilibrative nucleoside transporter inhibition. Enhanced adenosine signaling is associated with seizure termination and neuroprotection.

Figure 173

Signaling pathway integration between opioid and cannabinoid receptor systems in epilepsy. Bidirectional modulation between these systems suggests complex pharmacological interactions.

Figure 174

Adenosine A2A receptor structure and potential indirect modulation by phytocannabinoids. A2A receptors in the striatum and hippocampus may contribute to network-level effects on seizure propagation.

Figure 175

Receptor occupancy model for phytocannabinoids at opioid receptor subtypes. While direct binding affinity is modest, functional interactions between the two systems appear to be physiologically relevant.

Figure 176

Pentameric architecture of neuronal nicotinic acetylcholine receptors (nAChRs) and phytocannabinoid modulation sites. Certain nAChR subtypes are directly implicated in autosomal dominant nocturnal frontal lobe epilepsy.

Figure 177

Alpha-7 nicotinic receptor structure and its negative modulation by select phytocannabinoids. Alpha-7 nAChR inhibition may reduce excitatory cholinergic drive in epileptogenic circuits.

Figure 178

Subunit assembly patterns of nAChRs relevant to phytocannabinoid interaction. Alpha-4/beta-2 containing receptors show distinct sensitivity profiles compared to alpha-7 homomeric channels.

Figure 179

Ion permeation pathway through nicotinic receptor channels and the impact of phytocannabinoid allosteric modulation. Changes in calcium permeability through nAChRs may influence downstream seizure-related signaling.

Figure 180

Cholinergic synapse model showing sites of phytocannabinoid action on nicotinic transmission. Both presynaptic and postsynaptic nAChR modulation may contribute to the net effect on neuronal excitability.

Figure 181

Pentameric architecture of neuronal nicotinic acetylcholine receptors (nAChRs) and phytocannabinoid modulation sites. Certain nAChR subtypes are directly implicated in autosomal dominant nocturnal frontal lobe epilepsy.

Figure 182

Alpha-7 nicotinic receptor structure and its negative modulation by select phytocannabinoids. Alpha-7 nAChR inhibition may reduce excitatory cholinergic drive in epileptogenic circuits.

Figure 183

Subunit assembly patterns of nAChRs relevant to phytocannabinoid interaction. Alpha-4/beta-2 containing receptors show distinct sensitivity profiles compared to alpha-7 homomeric channels.

Figure 184

Ion permeation pathway through nicotinic receptor channels and the impact of phytocannabinoid allosteric modulation. Changes in calcium permeability through nAChRs may influence downstream seizure-related signaling.

Figure 185

Cholinergic synapse model showing sites of phytocannabinoid action on nicotinic transmission. Both presynaptic and postsynaptic nAChR modulation may contribute to the net effect on neuronal excitability.

Figure 186

Pentameric architecture of neuronal nicotinic acetylcholine receptors (nAChRs) and phytocannabinoid modulation sites. Certain nAChR subtypes are directly implicated in autosomal dominant nocturnal frontal lobe epilepsy.

Figure 187

Alpha-7 nicotinic receptor structure and its negative modulation by select phytocannabinoids. Alpha-7 nAChR inhibition may reduce excitatory cholinergic drive in epileptogenic circuits.

Figure 188

Subunit assembly patterns of nAChRs relevant to phytocannabinoid interaction. Alpha-4/beta-2 containing receptors show distinct sensitivity profiles compared to alpha-7 homomeric channels.

Figure 189

Ion permeation pathway through nicotinic receptor channels and the impact of phytocannabinoid allosteric modulation. Changes in calcium permeability through nAChRs may influence downstream seizure-related signaling.

Figure 190

Cholinergic synapse model showing sites of phytocannabinoid action on nicotinic transmission. Both presynaptic and postsynaptic nAChR modulation may contribute to the net effect on neuronal excitability.

Figure 191

Pentameric architecture of neuronal nicotinic acetylcholine receptors (nAChRs) and phytocannabinoid modulation sites. Certain nAChR subtypes are directly implicated in autosomal dominant nocturnal frontal lobe epilepsy.

Figure 192

Alpha-7 nicotinic receptor structure and its negative modulation by select phytocannabinoids. Alpha-7 nAChR inhibition may reduce excitatory cholinergic drive in epileptogenic circuits.

Figure 193

Subunit assembly patterns of nAChRs relevant to phytocannabinoid interaction. Alpha-4/beta-2 containing receptors show distinct sensitivity profiles compared to alpha-7 homomeric channels.

Figure 194

Ion permeation pathway through nicotinic receptor channels and the impact of phytocannabinoid allosteric modulation. Changes in calcium permeability through nAChRs may influence downstream seizure-related signaling.

Figure 195

Cholinergic synapse model showing sites of phytocannabinoid action on nicotinic transmission. Both presynaptic and postsynaptic nAChR modulation may contribute to the net effect on neuronal excitability.

Figure 196

Structural model of voltage-gated sodium channel (Nav) alpha subunit and phytocannabinoid binding sites. Nav channel blockade is a well-established mechanism of conventional antiepileptic drugs, and some phytocannabinoids show similar activity.

Figure 197

Nav1.1 through Nav1.6 channel subtype expression in cortical neurons. Mutations in SCN1A (Nav1.1) cause Dravet syndrome, the epilepsy subtype most responsive to cannabidiol treatment.

Figure 198

Pore-blocking mechanism of phytocannabinoids at voltage-gated sodium channels. State-dependent binding to inactivated Nav channels may provide use-dependent seizure suppression.

Figure 199

Gating kinetics of sodium channels in the presence and absence of phytocannabinoid modulators. Shifts in voltage dependence of inactivation indicate stabilization of the inactivated channel state.

Figure 200

Sodium channel auxiliary subunit interactions and their influence on phytocannabinoid sensitivity. Beta subunits modify channel gating properties and may alter the efficacy of cannabinoid-mediated block.

Figure 201

Structural model of voltage-gated sodium channel (Nav) alpha subunit and phytocannabinoid binding sites. Nav channel blockade is a well-established mechanism of conventional antiepileptic drugs, and some phytocannabinoids show similar activity.

Figure 202

Nav1.1 through Nav1.6 channel subtype expression in cortical neurons. Mutations in SCN1A (Nav1.1) cause Dravet syndrome, the epilepsy subtype most responsive to cannabidiol treatment.

Figure 203

Pore-blocking mechanism of phytocannabinoids at voltage-gated sodium channels. State-dependent binding to inactivated Nav channels may provide use-dependent seizure suppression.

Figure 204

Gating kinetics of sodium channels in the presence and absence of phytocannabinoid modulators. Shifts in voltage dependence of inactivation indicate stabilization of the inactivated channel state.

Figure 205

Sodium channel auxiliary subunit interactions and their influence on phytocannabinoid sensitivity. Beta subunits modify channel gating properties and may alter the efficacy of cannabinoid-mediated block.

Figure 206

Structural model of voltage-gated sodium channel (Nav) alpha subunit and phytocannabinoid binding sites. Nav channel blockade is a well-established mechanism of conventional antiepileptic drugs, and some phytocannabinoids show similar activity.

Figure 207

Nav1.1 through Nav1.6 channel subtype expression in cortical neurons. Mutations in SCN1A (Nav1.1) cause Dravet syndrome, the epilepsy subtype most responsive to cannabidiol treatment.

Figure 208

Pore-blocking mechanism of phytocannabinoids at voltage-gated sodium channels. State-dependent binding to inactivated Nav channels may provide use-dependent seizure suppression.

Figure 209

Gating kinetics of sodium channels in the presence and absence of phytocannabinoid modulators. Shifts in voltage dependence of inactivation indicate stabilization of the inactivated channel state.

Figure 210

Sodium channel auxiliary subunit interactions and their influence on phytocannabinoid sensitivity. Beta subunits modify channel gating properties and may alter the efficacy of cannabinoid-mediated block.

Figure 211

Structural model of voltage-gated sodium channel (Nav) alpha subunit and phytocannabinoid binding sites. Nav channel blockade is a well-established mechanism of conventional antiepileptic drugs, and some phytocannabinoids show similar activity.

Figure 212

Nav1.1 through Nav1.6 channel subtype expression in cortical neurons. Mutations in SCN1A (Nav1.1) cause Dravet syndrome, the epilepsy subtype most responsive to cannabidiol treatment.

Figure 213

Pore-blocking mechanism of phytocannabinoids at voltage-gated sodium channels. State-dependent binding to inactivated Nav channels may provide use-dependent seizure suppression.

Figure 214

Gating kinetics of sodium channels in the presence and absence of phytocannabinoid modulators. Shifts in voltage dependence of inactivation indicate stabilization of the inactivated channel state.

Figure 215

Sodium channel auxiliary subunit interactions and their influence on phytocannabinoid sensitivity. Beta subunits modify channel gating properties and may alter the efficacy of cannabinoid-mediated block.

Figure 216

T-type calcium channel (Cav3.x) structure and phytocannabinoid inhibition sites. T-type channels are critically involved in thalamocortical oscillations underlying absence seizures.

Figure 217

Calcium current recordings showing dose-dependent inhibition by phytocannabinoid compounds. Reduction of T-type calcium currents may be particularly relevant for absence epilepsy.

Figure 218

L-type calcium channel (Cav1.x) architecture and its modulation by select phytocannabinoids. L-type channels contribute to dendritic calcium signaling and synaptic plasticity in epileptogenic networks.

Figure 219

Comparative potency of phytocannabinoids at different voltage-gated calcium channel subtypes. Selectivity for T-type over L-type channels suggests a favorable profile for certain seizure types.

Figure 220

Calcium channel beta subunit interactions and their role in determining phytocannabinoid sensitivity. Auxiliary subunits modulate surface expression and gating, indirectly affecting drug potency.

Figure 221

T-type calcium channel (Cav3.x) structure and phytocannabinoid inhibition sites. T-type channels are critically involved in thalamocortical oscillations underlying absence seizures.

Figure 222

Calcium current recordings showing dose-dependent inhibition by phytocannabinoid compounds. Reduction of T-type calcium currents may be particularly relevant for absence epilepsy.

Figure 223

L-type calcium channel (Cav1.x) architecture and its modulation by select phytocannabinoids. L-type channels contribute to dendritic calcium signaling and synaptic plasticity in epileptogenic networks.

Figure 224

Comparative potency of phytocannabinoids at different voltage-gated calcium channel subtypes. Selectivity for T-type over L-type channels suggests a favorable profile for certain seizure types.

Figure 225

Calcium channel beta subunit interactions and their role in determining phytocannabinoid sensitivity. Auxiliary subunits modulate surface expression and gating, indirectly affecting drug potency.

Figure 226

T-type calcium channel (Cav3.x) structure and phytocannabinoid inhibition sites. T-type channels are critically involved in thalamocortical oscillations underlying absence seizures.

Figure 227

Calcium current recordings showing dose-dependent inhibition by phytocannabinoid compounds. Reduction of T-type calcium currents may be particularly relevant for absence epilepsy.

Figure 228

L-type calcium channel (Cav1.x) architecture and its modulation by select phytocannabinoids. L-type channels contribute to dendritic calcium signaling and synaptic plasticity in epileptogenic networks.

Figure 229

Comparative potency of phytocannabinoids at different voltage-gated calcium channel subtypes. Selectivity for T-type over L-type channels suggests a favorable profile for certain seizure types.

Figure 230

Calcium channel beta subunit interactions and their role in determining phytocannabinoid sensitivity. Auxiliary subunits modulate surface expression and gating, indirectly affecting drug potency.

Figure 231

T-type calcium channel (Cav3.x) structure and phytocannabinoid inhibition sites. T-type channels are critically involved in thalamocortical oscillations underlying absence seizures.

Figure 232

Calcium current recordings showing dose-dependent inhibition by phytocannabinoid compounds. Reduction of T-type calcium currents may be particularly relevant for absence epilepsy.

Figure 233

L-type calcium channel (Cav1.x) architecture and its modulation by select phytocannabinoids. L-type channels contribute to dendritic calcium signaling and synaptic plasticity in epileptogenic networks.

Figure 234

Comparative potency of phytocannabinoids at different voltage-gated calcium channel subtypes. Selectivity for T-type over L-type channels suggests a favorable profile for certain seizure types.

Figure 235

Calcium channel beta subunit interactions and their role in determining phytocannabinoid sensitivity. Auxiliary subunits modulate surface expression and gating, indirectly affecting drug potency.

Figure 236

Kv7 (KCNQ) potassium channel structure and potential enhancement by phytocannabinoid compounds. Kv7 channel openers are established antiepileptic agents, and cannabinoid-mediated enhancement could contribute to seizure control.

Figure 237

M-current (Kv7.2/7.3) recording showing modulation by phytocannabinoid application. Enhancement of the M-current stabilizes neuronal resting membrane potential and reduces repetitive firing.

Figure 238

Structural basis for potassium channel selectivity filter interactions with phytocannabinoid molecules. The narrow selectivity filter of K+ channels imposes specific structural requirements on modulatory compounds.

Figure 239

Inward-rectifier potassium channel (Kir) family members and their response to phytocannabinoid modulation. GIRK channels, activated downstream of CB1 receptors, mediate part of the cannabinoid-induced membrane hyperpolarization.

Figure 240

Two-pore domain potassium channel (K2P) structures and phytocannabinoid sensitivity. TREK and TASK channels represent leak conductances that set neuronal excitability thresholds.

Figure 241

Kv7 (KCNQ) potassium channel structure and potential enhancement by phytocannabinoid compounds. Kv7 channel openers are established antiepileptic agents, and cannabinoid-mediated enhancement could contribute to seizure control.

Figure 242

M-current (Kv7.2/7.3) recording showing modulation by phytocannabinoid application. Enhancement of the M-current stabilizes neuronal resting membrane potential and reduces repetitive firing.

Figure 243

Structural basis for potassium channel selectivity filter interactions with phytocannabinoid molecules. The narrow selectivity filter of K+ channels imposes specific structural requirements on modulatory compounds.

Figure 244

Inward-rectifier potassium channel (Kir) family members and their response to phytocannabinoid modulation. GIRK channels, activated downstream of CB1 receptors, mediate part of the cannabinoid-induced membrane hyperpolarization.

Figure 245

Two-pore domain potassium channel (K2P) structures and phytocannabinoid sensitivity. TREK and TASK channels represent leak conductances that set neuronal excitability thresholds.

Figure 246

Kv7 (KCNQ) potassium channel structure and potential enhancement by phytocannabinoid compounds. Kv7 channel openers are established antiepileptic agents, and cannabinoid-mediated enhancement could contribute to seizure control.

Figure 247

M-current (Kv7.2/7.3) recording showing modulation by phytocannabinoid application. Enhancement of the M-current stabilizes neuronal resting membrane potential and reduces repetitive firing.

Figure 248

Structural basis for potassium channel selectivity filter interactions with phytocannabinoid molecules. The narrow selectivity filter of K+ channels imposes specific structural requirements on modulatory compounds.

Figure 249

Inward-rectifier potassium channel (Kir) family members and their response to phytocannabinoid modulation. GIRK channels, activated downstream of CB1 receptors, mediate part of the cannabinoid-induced membrane hyperpolarization.

Figure 250

Two-pore domain potassium channel (K2P) structures and phytocannabinoid sensitivity. TREK and TASK channels represent leak conductances that set neuronal excitability thresholds.

Figure 251

Kv7 (KCNQ) potassium channel structure and potential enhancement by phytocannabinoid compounds. Kv7 channel openers are established antiepileptic agents, and cannabinoid-mediated enhancement could contribute to seizure control.

Figure 252

M-current (Kv7.2/7.3) recording showing modulation by phytocannabinoid application. Enhancement of the M-current stabilizes neuronal resting membrane potential and reduces repetitive firing.

Figure 253

Structural basis for potassium channel selectivity filter interactions with phytocannabinoid molecules. The narrow selectivity filter of K+ channels imposes specific structural requirements on modulatory compounds.

Figure 254

Inward-rectifier potassium channel (Kir) family members and their response to phytocannabinoid modulation. GIRK channels, activated downstream of CB1 receptors, mediate part of the cannabinoid-induced membrane hyperpolarization.

Figure 255

Two-pore domain potassium channel (K2P) structures and phytocannabinoid sensitivity. TREK and TASK channels represent leak conductances that set neuronal excitability thresholds.

Figure 256

PPAR-gamma nuclear receptor structure and phytocannabinoid ligand docking. Activation of PPAR-gamma by cannabinoids is associated with anti-inflammatory and neuroprotective gene transcription programs.

Figure 257

PPAR-alpha receptor and its activation by select phytocannabinoids. Nuclear receptor engagement represents a genomic mechanism of action distinct from rapid ion channel or GPCR effects.

Figure 258

Transcriptional regulation downstream of PPAR activation by phytocannabinoids in glial cells. Anti-inflammatory gene programs may reduce the neuroinflammatory component of chronic epilepsy.

Figure 259

Ligand binding domain of PPAR-gamma with cannabinoid agonist docked in the binding pocket. The broad ligand tolerance of PPAR-gamma accommodates structurally diverse phytocannabinoid molecules.

Figure 260

Nuclear receptor signaling timeline comparing rapid ionotropic effects with slower genomic mechanisms of phytocannabinoids. The dual action at both membrane and nuclear targets may explain sustained antiepileptic efficacy.

Figure 261

PPAR-gamma nuclear receptor structure and phytocannabinoid ligand docking. Activation of PPAR-gamma by cannabinoids is associated with anti-inflammatory and neuroprotective gene transcription programs.

Figure 262

PPAR-alpha receptor and its activation by select phytocannabinoids. Nuclear receptor engagement represents a genomic mechanism of action distinct from rapid ion channel or GPCR effects.

Figure 263

Transcriptional regulation downstream of PPAR activation by phytocannabinoids in glial cells. Anti-inflammatory gene programs may reduce the neuroinflammatory component of chronic epilepsy.

Figure 264

Ligand binding domain of PPAR-gamma with cannabinoid agonist docked in the binding pocket. The broad ligand tolerance of PPAR-gamma accommodates structurally diverse phytocannabinoid molecules.

Figure 265

Nuclear receptor signaling timeline comparing rapid ionotropic effects with slower genomic mechanisms of phytocannabinoids. The dual action at both membrane and nuclear targets may explain sustained antiepileptic efficacy.

Figure 266

PPAR-gamma nuclear receptor structure and phytocannabinoid ligand docking. Activation of PPAR-gamma by cannabinoids is associated with anti-inflammatory and neuroprotective gene transcription programs.

Figure 267

PPAR-alpha receptor and its activation by select phytocannabinoids. Nuclear receptor engagement represents a genomic mechanism of action distinct from rapid ion channel or GPCR effects.

Figure 268

Transcriptional regulation downstream of PPAR activation by phytocannabinoids in glial cells. Anti-inflammatory gene programs may reduce the neuroinflammatory component of chronic epilepsy.

Figure 269

Ligand binding domain of PPAR-gamma with cannabinoid agonist docked in the binding pocket. The broad ligand tolerance of PPAR-gamma accommodates structurally diverse phytocannabinoid molecules.

Figure 270

Nuclear receptor signaling timeline comparing rapid ionotropic effects with slower genomic mechanisms of phytocannabinoids. The dual action at both membrane and nuclear targets may explain sustained antiepileptic efficacy.

Figure 271

Integrated signaling network showing convergent pathways through which phytocannabinoids modulate neuronal excitability. Multiple receptor and channel targets act synergistically to influence seizure threshold.

Figure 272

Summary diagram of all receptor families responsive to phytocannabinoids in the context of epilepsy. The multi-target pharmacology of cannabis-derived compounds differentiates them from conventional single-target antiepileptic drugs.

Figure 273

Network-level model of phytocannabinoid effects on excitatory-inhibitory balance in epileptic circuits. The combined modulation of glutamatergic, GABAergic, and neuromodulatory systems determines the net anticonvulsant effect.

Figure 274

Therapeutic window illustration for phytocannabinoid dosing in epilepsy management. Biphasic dose-response relationships at several target receptors complicate the optimization of cannabinoid-based therapies.

Figure 275

Phylogenetic comparison of receptor sensitivity to phytocannabinoids across species used in epilepsy research. Species differences in receptor expression and pharmacology affect the translational relevance of preclinical findings.

Figure 276

Integrated signaling network showing convergent pathways through which phytocannabinoids modulate neuronal excitability. Multiple receptor and channel targets act synergistically to influence seizure threshold.

Figure 277

Summary diagram of all receptor families responsive to phytocannabinoids in the context of epilepsy. The multi-target pharmacology of cannabis-derived compounds differentiates them from conventional single-target antiepileptic drugs.

Figure 278

Network-level model of phytocannabinoid effects on excitatory-inhibitory balance in epileptic circuits. The combined modulation of glutamatergic, GABAergic, and neuromodulatory systems determines the net anticonvulsant effect.

Figure 279

Therapeutic window illustration for phytocannabinoid dosing in epilepsy management. Biphasic dose-response relationships at several target receptors complicate the optimization of cannabinoid-based therapies.

Figure 280

Phylogenetic comparison of receptor sensitivity to phytocannabinoids across species used in epilepsy research. Species differences in receptor expression and pharmacology affect the translational relevance of preclinical findings.

Figure 281

Integrated signaling network showing convergent pathways through which phytocannabinoids modulate neuronal excitability. Multiple receptor and channel targets act synergistically to influence seizure threshold.

Figure 282

Summary diagram of all receptor families responsive to phytocannabinoids in the context of epilepsy. The multi-target pharmacology of cannabis-derived compounds differentiates them from conventional single-target antiepileptic drugs.

Figure 283

Network-level model of phytocannabinoid effects on excitatory-inhibitory balance in epileptic circuits. The combined modulation of glutamatergic, GABAergic, and neuromodulatory systems determines the net anticonvulsant effect.

Figure 284

Therapeutic window illustration for phytocannabinoid dosing in epilepsy management. Biphasic dose-response relationships at several target receptors complicate the optimization of cannabinoid-based therapies.

Figure 285

Neural pathway components potentially modulated by cannabis-derived compounds in the context of epilepsy management are presented. The endocannabinoid system intersects with multiple neurotransmitter systems.

Figure 286

Pharmacological interactions between phytocannabinoids and receptor subtypes associated with seizure threshold regulation are mapped. Both CB1 and non-CB receptor mechanisms appear to be involved.

Figure 287

Cellular mechanisms through which phytocannabinoids may reduce neuronal hyperexcitability are diagrammed. GABAergic and glutamatergic signaling represent critical points of intervention.

Figure 288

Transient receptor potential (TRP) channel interactions with phytocannabinoid compounds are illustrated in the context of epilepsy research. TRP channels represent emerging targets for seizure control.

Figure 289

Endocannabinoid system components relevant to phytocannabinoid-mediated seizure suppression are depicted. Enzymatic degradation pathways and receptor distributions influence therapeutic outcomes.

Figure 290

Receptor binding interactions between phytocannabinoids and neuronal targets implicated in seizure modulation are depicted. The review examines how compounds like CBD and THC may interact with multiple receptor systems beyond the classical endocannabinoid pathway.

Figure 291

Ion channel gating mechanisms potentially affected by phytocannabinoid compounds in epileptic neural tissue are illustrated. Voltage-gated sodium and calcium channels represent key targets for anticonvulsant activity.

Figure 292

Molecular signaling cascades linking phytocannabinoid receptor activation to downstream anticonvulsant effects are outlined. Multiple parallel pathways may contribute to seizure suppression.

Figure 293

Structural features of a phytocannabinoid compound relevant to its interaction with neural receptors involved in epilepsy are shown. Structure-activity relationships help explain differential anticonvulsant potency.

Figure 294

A receptor or channel subtype investigated for its role in mediating phytocannabinoid effects on seizure activity is depicted. Understanding these targets may inform the development of novel antiepileptic therapies.

Figure 295

Neural pathway components potentially modulated by cannabis-derived compounds in the context of epilepsy management are presented. The endocannabinoid system intersects with multiple neurotransmitter systems.

Figure 296

Molecular docking or interaction model between a phytocannabinoid and its neuronal target is presented. Computational approaches help predict receptor-ligand binding characteristics.

Figure 297

Membrane receptor complex organization relevant to phytocannabinoid signaling in epileptic tissue is depicted. Receptor heterodimerization may influence pharmacological responses.

Figure 298

Lipid signaling pathways connecting endocannabinoid metabolism to seizure modulation are outlined. Phytocannabinoids may alter endogenous lipid mediator levels.

Figure 299

Synaptic transmission elements modulated by phytocannabinoid compounds are shown in the context of epileptiform activity. Presynaptic and postsynaptic mechanisms both contribute to anticonvulsant effects.

Figure 300

Receptor pharmacology data for a phytocannabinoid at targets implicated in seizure modulation are presented. Binding affinity and functional selectivity vary across receptor subtypes.

Figure 301

A molecular target potentially mediating the anticonvulsant effects of cannabis-derived compounds is illustrated. Preclinical evidence suggests involvement in seizure threshold regulation.

Figure 302

Structural comparison of phytocannabinoid compounds with known anticonvulsant properties is shown. Subtle molecular differences influence receptor selectivity and therapeutic potential.

Figure 303

Signal transduction pathways activated by phytocannabinoids in neural tissue are mapped, highlighting connections to epilepsy-relevant mechanisms. Both excitatory and inhibitory neurotransmission may be affected.

Figure 304

Channel conductance properties relevant to phytocannabinoid modulation of neuronal excitability are depicted. Altered ion flux through these channels may reduce seizure susceptibility.

Figure 305

Neuroanatomical distribution of receptors targeted by phytocannabinoids in brain regions associated with seizure generation is illustrated. Regional expression patterns influence therapeutic efficacy.

Figure 306

Molecular docking or interaction model between a phytocannabinoid and its neuronal target is presented. Computational approaches help predict receptor-ligand binding characteristics.

Figure 307

Membrane receptor complex organization relevant to phytocannabinoid signaling in epileptic tissue is depicted. Receptor heterodimerization may influence pharmacological responses.

Figure 308

Lipid signaling pathways connecting endocannabinoid metabolism to seizure modulation are outlined. Phytocannabinoids may alter endogenous lipid mediator levels.

Figure 309

Synaptic transmission elements modulated by phytocannabinoid compounds are shown in the context of epileptiform activity. Presynaptic and postsynaptic mechanisms both contribute to anticonvulsant effects.

Figure 310

Receptor pharmacology data for a phytocannabinoid at targets implicated in seizure modulation are presented. Binding affinity and functional selectivity vary across receptor subtypes.

Figure 311

A molecular target potentially mediating the anticonvulsant effects of cannabis-derived compounds is illustrated. Preclinical evidence suggests involvement in seizure threshold regulation.

Figure 312

Structural comparison of phytocannabinoid compounds with known anticonvulsant properties is shown. Subtle molecular differences influence receptor selectivity and therapeutic potential.

Figure 313

Signal transduction pathways activated by phytocannabinoids in neural tissue are mapped, highlighting connections to epilepsy-relevant mechanisms. Both excitatory and inhibitory neurotransmission may be affected.

Figure 314

Channel conductance properties relevant to phytocannabinoid modulation of neuronal excitability are depicted. Altered ion flux through these channels may reduce seizure susceptibility.

Figure 315

Neuroanatomical distribution of receptors targeted by phytocannabinoids in brain regions associated with seizure generation is illustrated. Regional expression patterns influence therapeutic efficacy.

Figure 316

Molecular docking or interaction model between a phytocannabinoid and its neuronal target is presented. Computational approaches help predict receptor-ligand binding characteristics.

Figure 317

Membrane receptor complex organization relevant to phytocannabinoid signaling in epileptic tissue is depicted. Receptor heterodimerization may influence pharmacological responses.

Figure 318

Lipid signaling pathways connecting endocannabinoid metabolism to seizure modulation are outlined. Phytocannabinoids may alter endogenous lipid mediator levels.

Figure 319

Synaptic transmission elements modulated by phytocannabinoid compounds are shown in the context of epileptiform activity. Presynaptic and postsynaptic mechanisms both contribute to anticonvulsant effects.

Figure 320

Receptor pharmacology data for a phytocannabinoid at targets implicated in seizure modulation are presented. Binding affinity and functional selectivity vary across receptor subtypes.

Figure 321

A molecular target potentially mediating the anticonvulsant effects of cannabis-derived compounds is illustrated. Preclinical evidence suggests involvement in seizure threshold regulation.

Figure 322

Structural comparison of phytocannabinoid compounds with known anticonvulsant properties is shown. Subtle molecular differences influence receptor selectivity and therapeutic potential.

Figure 323

Signal transduction pathways activated by phytocannabinoids in neural tissue are mapped, highlighting connections to epilepsy-relevant mechanisms. Both excitatory and inhibitory neurotransmission may be affected.

Figure 324

Channel conductance properties relevant to phytocannabinoid modulation of neuronal excitability are depicted. Altered ion flux through these channels may reduce seizure susceptibility.

Figure 325

Neuroanatomical distribution of receptors targeted by phytocannabinoids in brain regions associated with seizure generation is illustrated. Regional expression patterns influence therapeutic efficacy.

Figure 326

Molecular docking or interaction model between a phytocannabinoid and its neuronal target is presented. Computational approaches help predict receptor-ligand binding characteristics.

Figure 327

Membrane receptor complex organization relevant to phytocannabinoid signaling in epileptic tissue is depicted. Receptor heterodimerization may influence pharmacological responses.

Figure 328

Lipid signaling pathways connecting endocannabinoid metabolism to seizure modulation are outlined. Phytocannabinoids may alter endogenous lipid mediator levels.

Figure 329

Synaptic transmission elements modulated by phytocannabinoid compounds are shown in the context of epileptiform activity. Presynaptic and postsynaptic mechanisms both contribute to anticonvulsant effects.

Figure 330

Receptor pharmacology data for a phytocannabinoid at targets implicated in seizure modulation are presented. Binding affinity and functional selectivity vary across receptor subtypes.

Figure 331

A molecular target potentially mediating the anticonvulsant effects of cannabis-derived compounds is illustrated. Preclinical evidence suggests involvement in seizure threshold regulation.

Figure 332

Structural comparison of phytocannabinoid compounds with known anticonvulsant properties is shown. Subtle molecular differences influence receptor selectivity and therapeutic potential.

Figure 333

Signal transduction pathways activated by phytocannabinoids in neural tissue are mapped, highlighting connections to epilepsy-relevant mechanisms. Both excitatory and inhibitory neurotransmission may be affected.

Figure 334

Channel conductance properties relevant to phytocannabinoid modulation of neuronal excitability are depicted. Altered ion flux through these channels may reduce seizure susceptibility.

Figure 335

Neuroanatomical distribution of receptors targeted by phytocannabinoids in brain regions associated with seizure generation is illustrated. Regional expression patterns influence therapeutic efficacy.

Figure 336

Molecular docking or interaction model between a phytocannabinoid and its neuronal target is presented. Computational approaches help predict receptor-ligand binding characteristics.

Figure 337

Membrane receptor complex organization relevant to phytocannabinoid signaling in epileptic tissue is depicted. Receptor heterodimerization may influence pharmacological responses.

Figure 338

Lipid signaling pathways connecting endocannabinoid metabolism to seizure modulation are outlined. Phytocannabinoids may alter endogenous lipid mediator levels.

Figure 339

Synaptic transmission elements modulated by phytocannabinoid compounds are shown in the context of epileptiform activity. Presynaptic and postsynaptic mechanisms both contribute to anticonvulsant effects.

Figure 340

Receptor pharmacology data for a phytocannabinoid at targets implicated in seizure modulation are presented. Binding affinity and functional selectivity vary across receptor subtypes.

Figure 341

A schematic of receptor-channel interactions relevant to phytocannabinoid effects on epileptic seizures is presented. Cross-talk between receptor systems may enhance anticonvulsant efficacy.

Figure 342

Calcium signaling pathways modulated by phytocannabinoids in neurons are depicted. Altered intracellular calcium dynamics may reduce seizure propagation.

Figure 343

Potassium channel subtypes potentially targeted by phytocannabinoid compounds for seizure control are illustrated. Enhanced potassium conductance could stabilize neuronal membrane potential.

Figure 344

Glial cell interactions with phytocannabinoids that may influence seizure susceptibility are mapped. Astrocytic and microglial cannabinoid receptors represent additional therapeutic targets.

Figure 345

Neurotransmitter release mechanisms affected by phytocannabinoid compounds at synapses in epileptic circuits are shown. Retrograde signaling through the endocannabinoid system modulates vesicular release.

Figure 346

Metabolic pathways for phytocannabinoid biotransformation relevant to anticonvulsant activity are depicted. Active metabolites may contribute to therapeutic effects.

Figure 347

Gene expression changes associated with phytocannabinoid exposure in neural tissue are outlined. Transcriptional regulation may underlie long-term anticonvulsant effects.

Figure 348

Neuroprotective mechanisms of phytocannabinoids relevant to seizure-induced neuronal damage are illustrated. Anti-inflammatory and antioxidant properties may complement direct anticonvulsant action.

Figure 349

Dose-response relationships for phytocannabinoid effects on seizure-related targets are depicted. Biphasic responses have been observed for several receptor systems.

Figure 350

Intracellular signaling cascade components affected by phytocannabinoid receptor activation are illustrated. Second messenger systems link receptor binding to changes in neuronal excitability.

Figure 351

A schematic of receptor-channel interactions relevant to phytocannabinoid effects on epileptic seizures is presented. Cross-talk between receptor systems may enhance anticonvulsant efficacy.

Figure 352

Calcium signaling pathways modulated by phytocannabinoids in neurons are depicted. Altered intracellular calcium dynamics may reduce seizure propagation.

Figure 353

Potassium channel subtypes potentially targeted by phytocannabinoid compounds for seizure control are illustrated. Enhanced potassium conductance could stabilize neuronal membrane potential.

Figure 354

Glial cell interactions with phytocannabinoids that may influence seizure susceptibility are mapped. Astrocytic and microglial cannabinoid receptors represent additional therapeutic targets.

Figure 355

Neurotransmitter release mechanisms affected by phytocannabinoid compounds at synapses in epileptic circuits are shown. Retrograde signaling through the endocannabinoid system modulates vesicular release.

Figure 356

Metabolic pathways for phytocannabinoid biotransformation relevant to anticonvulsant activity are depicted. Active metabolites may contribute to therapeutic effects.

Figure 357

Gene expression changes associated with phytocannabinoid exposure in neural tissue are outlined. Transcriptional regulation may underlie long-term anticonvulsant effects.

Figure 358

Neuroprotective mechanisms of phytocannabinoids relevant to seizure-induced neuronal damage are illustrated. Anti-inflammatory and antioxidant properties may complement direct anticonvulsant action.

Figure 359

Dose-response relationships for phytocannabinoid effects on seizure-related targets are depicted. Biphasic responses have been observed for several receptor systems.

Figure 360

Intracellular signaling cascade components affected by phytocannabinoid receptor activation are illustrated. Second messenger systems link receptor binding to changes in neuronal excitability.

Figure 361

A schematic of receptor-channel interactions relevant to phytocannabinoid effects on epileptic seizures is presented. Cross-talk between receptor systems may enhance anticonvulsant efficacy.

Figure 362

Calcium signaling pathways modulated by phytocannabinoids in neurons are depicted. Altered intracellular calcium dynamics may reduce seizure propagation.

Figure 363

Potassium channel subtypes potentially targeted by phytocannabinoid compounds for seizure control are illustrated. Enhanced potassium conductance could stabilize neuronal membrane potential.

Figure 364

Glial cell interactions with phytocannabinoids that may influence seizure susceptibility are mapped. Astrocytic and microglial cannabinoid receptors represent additional therapeutic targets.

Figure 365

Neurotransmitter release mechanisms affected by phytocannabinoid compounds at synapses in epileptic circuits are shown. Retrograde signaling through the endocannabinoid system modulates vesicular release.

Figure 366

Metabolic pathways for phytocannabinoid biotransformation relevant to anticonvulsant activity are depicted. Active metabolites may contribute to therapeutic effects.

Figure 367

Gene expression changes associated with phytocannabinoid exposure in neural tissue are outlined. Transcriptional regulation may underlie long-term anticonvulsant effects.

Figure 368

Neuroprotective mechanisms of phytocannabinoids relevant to seizure-induced neuronal damage are illustrated. Anti-inflammatory and antioxidant properties may complement direct anticonvulsant action.

Figure 369

Dose-response relationships for phytocannabinoid effects on seizure-related targets are depicted. Biphasic responses have been observed for several receptor systems.

Figure 370

Intracellular signaling cascade components affected by phytocannabinoid receptor activation are illustrated. Second messenger systems link receptor binding to changes in neuronal excitability.

Figure 371

A schematic of receptor-channel interactions relevant to phytocannabinoid effects on epileptic seizures is presented. Cross-talk between receptor systems may enhance anticonvulsant efficacy.

Figure 372

Calcium signaling pathways modulated by phytocannabinoids in neurons are depicted. Altered intracellular calcium dynamics may reduce seizure propagation.

Figure 373

Potassium channel subtypes potentially targeted by phytocannabinoid compounds for seizure control are illustrated. Enhanced potassium conductance could stabilize neuronal membrane potential.

Figure 374

Glial cell interactions with phytocannabinoids that may influence seizure susceptibility are mapped. Astrocytic and microglial cannabinoid receptors represent additional therapeutic targets.

Figure 375

Neurotransmitter release mechanisms affected by phytocannabinoid compounds at synapses in epileptic circuits are shown. Retrograde signaling through the endocannabinoid system modulates vesicular release.

Figure 376

Metabolic pathways for phytocannabinoid biotransformation relevant to anticonvulsant activity are depicted. Active metabolites may contribute to therapeutic effects.

Figure 377

Gene expression changes associated with phytocannabinoid exposure in neural tissue are outlined. Transcriptional regulation may underlie long-term anticonvulsant effects.

Figure 378

Neuroprotective mechanisms of phytocannabinoids relevant to seizure-induced neuronal damage are illustrated. Anti-inflammatory and antioxidant properties may complement direct anticonvulsant action.

Figure 379

Dose-response relationships for phytocannabinoid effects on seizure-related targets are depicted. Biphasic responses have been observed for several receptor systems.

Figure 380

Intracellular signaling cascade components affected by phytocannabinoid receptor activation are illustrated. Second messenger systems link receptor binding to changes in neuronal excitability.

Figure 381

A schematic of receptor-channel interactions relevant to phytocannabinoid effects on epileptic seizures is presented. Cross-talk between receptor systems may enhance anticonvulsant efficacy.

Figure 382

Calcium signaling pathways modulated by phytocannabinoids in neurons are depicted. Altered intracellular calcium dynamics may reduce seizure propagation.

Figure 383

Potassium channel subtypes potentially targeted by phytocannabinoid compounds for seizure control are illustrated. Enhanced potassium conductance could stabilize neuronal membrane potential.

Figure 384

Glial cell interactions with phytocannabinoids that may influence seizure susceptibility are mapped. Astrocytic and microglial cannabinoid receptors represent additional therapeutic targets.

Figure 385

Neurotransmitter release mechanisms affected by phytocannabinoid compounds at synapses in epileptic circuits are shown. Retrograde signaling through the endocannabinoid system modulates vesicular release.

Figure 386

Metabolic pathways for phytocannabinoid biotransformation relevant to anticonvulsant activity are depicted. Active metabolites may contribute to therapeutic effects.

Figure 387

Gene expression changes associated with phytocannabinoid exposure in neural tissue are outlined. Transcriptional regulation may underlie long-term anticonvulsant effects.

Figure 388

Neuroprotective mechanisms of phytocannabinoids relevant to seizure-induced neuronal damage are illustrated. Anti-inflammatory and antioxidant properties may complement direct anticonvulsant action.

Figure 389

Dose-response relationships for phytocannabinoid effects on seizure-related targets are depicted. Biphasic responses have been observed for several receptor systems.

Figure 390

Intracellular signaling cascade components affected by phytocannabinoid receptor activation are illustrated. Second messenger systems link receptor binding to changes in neuronal excitability.

Figure 391

Sodium channel inactivation states modulated by phytocannabinoid compounds are depicted. State-dependent blockade represents a common mechanism of anticonvulsant action.

Figure 392

Mitochondrial targets of phytocannabinoids potentially relevant to seizure pathophysiology are shown. Bioenergetic dysfunction contributes to neuronal hyperexcitability.

Figure 393

GABAergic interneuron subtypes affected by phytocannabinoid signaling are mapped. Differential modulation of interneuron populations influences seizure threshold.

Figure 394

Adenosine receptor interactions with phytocannabinoid compounds are illustrated. Adenosinergic mechanisms represent an additional pathway for seizure control.

Figure 395

Blood-brain barrier permeability considerations for phytocannabinoid delivery are depicted. Lipophilicity and transporter interactions influence CNS bioavailability.

Figure 396

Glycine receptor modulation by phytocannabinoid compounds is illustrated in relation to inhibitory neurotransmission. Enhanced glycinergic signaling may contribute to anticonvulsant effects.

Figure 397

Serotonin receptor subtypes targeted by phytocannabinoids with potential relevance to seizure modulation are depicted. 5-HT receptor agonism may complement cannabinoid receptor-mediated effects.

Figure 398

Nuclear receptor interactions of phytocannabinoid compounds are shown, including PPAR activation. Transcription factor modulation may influence anti-inflammatory and neuroprotective responses.

Figure 399

G-protein coupled receptor signaling bias induced by different phytocannabinoids is depicted. Biased agonism at CB1 receptors may explain differential therapeutic profiles.

Figure 400

Receptor desensitization kinetics following phytocannabinoid exposure are illustrated in the context of epilepsy treatment. Tolerance development may affect long-term therapeutic efficacy.

Figure 401

Sodium channel inactivation states modulated by phytocannabinoid compounds are depicted. State-dependent blockade represents a common mechanism of anticonvulsant action.

Figure 402

Mitochondrial targets of phytocannabinoids potentially relevant to seizure pathophysiology are shown. Bioenergetic dysfunction contributes to neuronal hyperexcitability.

Figure 403

GABAergic interneuron subtypes affected by phytocannabinoid signaling are mapped. Differential modulation of interneuron populations influences seizure threshold.

Figure 404

Adenosine receptor interactions with phytocannabinoid compounds are illustrated. Adenosinergic mechanisms represent an additional pathway for seizure control.

Figure 405

Blood-brain barrier permeability considerations for phytocannabinoid delivery are depicted. Lipophilicity and transporter interactions influence CNS bioavailability.

Figure 406

Glycine receptor modulation by phytocannabinoid compounds is illustrated in relation to inhibitory neurotransmission. Enhanced glycinergic signaling may contribute to anticonvulsant effects.

Figure 407

Serotonin receptor subtypes targeted by phytocannabinoids with potential relevance to seizure modulation are depicted. 5-HT receptor agonism may complement cannabinoid receptor-mediated effects.

Figure 408

Nuclear receptor interactions of phytocannabinoid compounds are shown, including PPAR activation. Transcription factor modulation may influence anti-inflammatory and neuroprotective responses.

Figure 409

G-protein coupled receptor signaling bias induced by different phytocannabinoids is depicted. Biased agonism at CB1 receptors may explain differential therapeutic profiles.

Figure 410

Receptor desensitization kinetics following phytocannabinoid exposure are illustrated in the context of epilepsy treatment. Tolerance development may affect long-term therapeutic efficacy.

Figure 411

Sodium channel inactivation states modulated by phytocannabinoid compounds are depicted. State-dependent blockade represents a common mechanism of anticonvulsant action.

Figure 412

Mitochondrial targets of phytocannabinoids potentially relevant to seizure pathophysiology are shown. Bioenergetic dysfunction contributes to neuronal hyperexcitability.

Figure 413

GABAergic interneuron subtypes affected by phytocannabinoid signaling are mapped. Differential modulation of interneuron populations influences seizure threshold.

Figure 414

Adenosine receptor interactions with phytocannabinoid compounds are illustrated. Adenosinergic mechanisms represent an additional pathway for seizure control.

Figure 415

Blood-brain barrier permeability considerations for phytocannabinoid delivery are depicted. Lipophilicity and transporter interactions influence CNS bioavailability.

Figure 416

Glycine receptor modulation by phytocannabinoid compounds is illustrated in relation to inhibitory neurotransmission. Enhanced glycinergic signaling may contribute to anticonvulsant effects.

Figure 417

Serotonin receptor subtypes targeted by phytocannabinoids with potential relevance to seizure modulation are depicted. 5-HT receptor agonism may complement cannabinoid receptor-mediated effects.

Figure 418

Nuclear receptor interactions of phytocannabinoid compounds are shown, including PPAR activation. Transcription factor modulation may influence anti-inflammatory and neuroprotective responses.

Figure 419

G-protein coupled receptor signaling bias induced by different phytocannabinoids is depicted. Biased agonism at CB1 receptors may explain differential therapeutic profiles.

Figure 420

Receptor desensitization kinetics following phytocannabinoid exposure are illustrated in the context of epilepsy treatment. Tolerance development may affect long-term therapeutic efficacy.

Figure 421

Sodium channel inactivation states modulated by phytocannabinoid compounds are depicted. State-dependent blockade represents a common mechanism of anticonvulsant action.

Figure 422

Mitochondrial targets of phytocannabinoids potentially relevant to seizure pathophysiology are shown. Bioenergetic dysfunction contributes to neuronal hyperexcitability.

Figure 423

GABAergic interneuron subtypes affected by phytocannabinoid signaling are mapped. Differential modulation of interneuron populations influences seizure threshold.

Figure 424

Adenosine receptor interactions with phytocannabinoid compounds are illustrated. Adenosinergic mechanisms represent an additional pathway for seizure control.

Figure 425

Blood-brain barrier permeability considerations for phytocannabinoid delivery are depicted. Lipophilicity and transporter interactions influence CNS bioavailability.

Figure 426

Glycine receptor modulation by phytocannabinoid compounds is illustrated in relation to inhibitory neurotransmission. Enhanced glycinergic signaling may contribute to anticonvulsant effects.

Figure 427

Serotonin receptor subtypes targeted by phytocannabinoids with potential relevance to seizure modulation are depicted. 5-HT receptor agonism may complement cannabinoid receptor-mediated effects.

Figure 428

Nuclear receptor interactions of phytocannabinoid compounds are shown, including PPAR activation. Transcription factor modulation may influence anti-inflammatory and neuroprotective responses.

Figure 429

G-protein coupled receptor signaling bias induced by different phytocannabinoids is depicted. Biased agonism at CB1 receptors may explain differential therapeutic profiles.

Figure 430

Receptor desensitization kinetics following phytocannabinoid exposure are illustrated in the context of epilepsy treatment. Tolerance development may affect long-term therapeutic efficacy.

Figure 431

Sodium channel inactivation states modulated by phytocannabinoid compounds are depicted. State-dependent blockade represents a common mechanism of anticonvulsant action.

Figure 432

Mitochondrial targets of phytocannabinoids potentially relevant to seizure pathophysiology are shown. Bioenergetic dysfunction contributes to neuronal hyperexcitability.

Figure 433

GABAergic interneuron subtypes affected by phytocannabinoid signaling are mapped. Differential modulation of interneuron populations influences seizure threshold.

Figure 434

Adenosine receptor interactions with phytocannabinoid compounds are illustrated. Adenosinergic mechanisms represent an additional pathway for seizure control.

Figure 435

Blood-brain barrier permeability considerations for phytocannabinoid delivery are depicted. Lipophilicity and transporter interactions influence CNS bioavailability.

Figure 436

Glycine receptor modulation by phytocannabinoid compounds is illustrated in relation to inhibitory neurotransmission. Enhanced glycinergic signaling may contribute to anticonvulsant effects.

Figure 437

Serotonin receptor subtypes targeted by phytocannabinoids with potential relevance to seizure modulation are depicted. 5-HT receptor agonism may complement cannabinoid receptor-mediated effects.

Figure 438

Nuclear receptor interactions of phytocannabinoid compounds are shown, including PPAR activation. Transcription factor modulation may influence anti-inflammatory and neuroprotective responses.

Figure 439

G-protein coupled receptor signaling bias induced by different phytocannabinoids is depicted. Biased agonism at CB1 receptors may explain differential therapeutic profiles.

Figure 440

Receptor desensitization kinetics following phytocannabinoid exposure are illustrated in the context of epilepsy treatment. Tolerance development may affect long-term therapeutic efficacy.

Figure 441

Anandamide and 2-AG metabolic enzyme interactions with phytocannabinoids are illustrated. Inhibition of endocannabinoid degradation may enhance endogenous anticonvulsant tone.

Figure 442

Orphan receptor GPR55 modulation by phytocannabinoids is shown in the context of epilepsy. GPR55 antagonism by CBD represents a non-classical cannabinoid mechanism.

Figure 443

Voltage-gated calcium channel subtypes affected by phytocannabinoid compounds are depicted. T-type calcium channel inhibition is associated with absence seizure control.

Figure 444

Inflammatory mediator pathways modulated by phytocannabinoids in epileptic brain tissue are outlined. Neuroinflammation contributes to seizure generation and progression.

Figure 445

Oxidative stress pathways relevant to phytocannabinoid neuroprotection in epilepsy are shown. Antioxidant properties of CBD and other phytocannabinoids may reduce seizure-related damage.

Figure 446

Aquaporin channel interactions with phytocannabinoid treatment are depicted. Water homeostasis disruption contributes to seizure-associated cerebral edema.

Figure 447

Opioid receptor cross-talk with cannabinoid signaling in the context of seizure control is illustrated. Mu and kappa opioid receptors may modulate phytocannabinoid efficacy.

Figure 448

Glutamate transporter modulation by phytocannabinoids is depicted. Enhanced glutamate clearance may reduce excitotoxicity associated with seizure activity.

Figure 449

Summary of multi-target pharmacology of phytocannabinoids relevant to epilepsy is presented. The polypharmacological profile of these compounds may explain their broad-spectrum anticonvulsant activity.

Figure 450

Vanilloid receptor (TRPV1) interactions with phytocannabinoid compounds are depicted in relation to seizure modulation. TRPV1 desensitization by CBD may contribute to its anticonvulsant properties.

Figure 451

Anandamide and 2-AG metabolic enzyme interactions with phytocannabinoids are illustrated. Inhibition of endocannabinoid degradation may enhance endogenous anticonvulsant tone.

Figure 452

Orphan receptor GPR55 modulation by phytocannabinoids is shown in the context of epilepsy. GPR55 antagonism by CBD represents a non-classical cannabinoid mechanism.

Figure 453

Voltage-gated calcium channel subtypes affected by phytocannabinoid compounds are depicted. T-type calcium channel inhibition is associated with absence seizure control.

Figure 454

Inflammatory mediator pathways modulated by phytocannabinoids in epileptic brain tissue are outlined. Neuroinflammation contributes to seizure generation and progression.

Figure 455

Oxidative stress pathways relevant to phytocannabinoid neuroprotection in epilepsy are shown. Antioxidant properties of CBD and other phytocannabinoids may reduce seizure-related damage.

Figure 456

Aquaporin channel interactions with phytocannabinoid treatment are depicted. Water homeostasis disruption contributes to seizure-associated cerebral edema.

Figure 457

Opioid receptor cross-talk with cannabinoid signaling in the context of seizure control is illustrated. Mu and kappa opioid receptors may modulate phytocannabinoid efficacy.

Figure 458

Glutamate transporter modulation by phytocannabinoids is depicted. Enhanced glutamate clearance may reduce excitotoxicity associated with seizure activity.

Figure 459

Summary of multi-target pharmacology of phytocannabinoids relevant to epilepsy is presented. The polypharmacological profile of these compounds may explain their broad-spectrum anticonvulsant activity.

Figure 460

Vanilloid receptor (TRPV1) interactions with phytocannabinoid compounds are depicted in relation to seizure modulation. TRPV1 desensitization by CBD may contribute to its anticonvulsant properties.

Figure 461

Anandamide and 2-AG metabolic enzyme interactions with phytocannabinoids are illustrated. Inhibition of endocannabinoid degradation may enhance endogenous anticonvulsant tone.

Figure 462

Orphan receptor GPR55 modulation by phytocannabinoids is shown in the context of epilepsy. GPR55 antagonism by CBD represents a non-classical cannabinoid mechanism.

Figure 463

Voltage-gated calcium channel subtypes affected by phytocannabinoid compounds are depicted. T-type calcium channel inhibition is associated with absence seizure control.

Figure 464

Inflammatory mediator pathways modulated by phytocannabinoids in epileptic brain tissue are outlined. Neuroinflammation contributes to seizure generation and progression.

Figure 465

Oxidative stress pathways relevant to phytocannabinoid neuroprotection in epilepsy are shown. Antioxidant properties of CBD and other phytocannabinoids may reduce seizure-related damage.

Figure 466

Aquaporin channel interactions with phytocannabinoid treatment are depicted. Water homeostasis disruption contributes to seizure-associated cerebral edema.

Figure 467

Opioid receptor cross-talk with cannabinoid signaling in the context of seizure control is illustrated. Mu and kappa opioid receptors may modulate phytocannabinoid efficacy.

Figure 468

Glutamate transporter modulation by phytocannabinoids is depicted. Enhanced glutamate clearance may reduce excitotoxicity associated with seizure activity.

Figure 469

Summary of multi-target pharmacology of phytocannabinoids relevant to epilepsy is presented. The polypharmacological profile of these compounds may explain their broad-spectrum anticonvulsant activity.

Figure 470

Vanilloid receptor (TRPV1) interactions with phytocannabinoid compounds are depicted in relation to seizure modulation. TRPV1 desensitization by CBD may contribute to its anticonvulsant properties.

Figure 471

Anandamide and 2-AG metabolic enzyme interactions with phytocannabinoids are illustrated. Inhibition of endocannabinoid degradation may enhance endogenous anticonvulsant tone.

Figure 472

Orphan receptor GPR55 modulation by phytocannabinoids is shown in the context of epilepsy. GPR55 antagonism by CBD represents a non-classical cannabinoid mechanism.

Figure 473

Voltage-gated calcium channel subtypes affected by phytocannabinoid compounds are depicted. T-type calcium channel inhibition is associated with absence seizure control.

Figure 474

Inflammatory mediator pathways modulated by phytocannabinoids in epileptic brain tissue are outlined. Neuroinflammation contributes to seizure generation and progression.

Figure 475

Oxidative stress pathways relevant to phytocannabinoid neuroprotection in epilepsy are shown. Antioxidant properties of CBD and other phytocannabinoids may reduce seizure-related damage.

Figure 476

Aquaporin channel interactions with phytocannabinoid treatment are depicted. Water homeostasis disruption contributes to seizure-associated cerebral edema.

Figure 477

Opioid receptor cross-talk with cannabinoid signaling in the context of seizure control is illustrated. Mu and kappa opioid receptors may modulate phytocannabinoid efficacy.

Figure 478

Glutamate transporter modulation by phytocannabinoids is depicted. Enhanced glutamate clearance may reduce excitotoxicity associated with seizure activity.

Figure 479

Summary of multi-target pharmacology of phytocannabinoids relevant to epilepsy is presented. The polypharmacological profile of these compounds may explain their broad-spectrum anticonvulsant activity.

Figure 480

Vanilloid receptor (TRPV1) interactions with phytocannabinoid compounds are depicted in relation to seizure modulation. TRPV1 desensitization by CBD may contribute to its anticonvulsant properties.

Figure 481

Anandamide and 2-AG metabolic enzyme interactions with phytocannabinoids are illustrated. Inhibition of endocannabinoid degradation may enhance endogenous anticonvulsant tone.

Figure 482

Orphan receptor GPR55 modulation by phytocannabinoids is shown in the context of epilepsy. GPR55 antagonism by CBD represents a non-classical cannabinoid mechanism.

Figure 483

Voltage-gated calcium channel subtypes affected by phytocannabinoid compounds are depicted. T-type calcium channel inhibition is associated with absence seizure control.

Figure 484

Inflammatory mediator pathways modulated by phytocannabinoids in epileptic brain tissue are outlined. Neuroinflammation contributes to seizure generation and progression.

Figure 485

Oxidative stress pathways relevant to phytocannabinoid neuroprotection in epilepsy are shown. Antioxidant properties of CBD and other phytocannabinoids may reduce seizure-related damage.

Figure 486

Aquaporin channel interactions with phytocannabinoid treatment are depicted. Water homeostasis disruption contributes to seizure-associated cerebral edema.

Figure 487

Opioid receptor cross-talk with cannabinoid signaling in the context of seizure control is illustrated. Mu and kappa opioid receptors may modulate phytocannabinoid efficacy.

Figure 488

Glutamate transporter modulation by phytocannabinoids is depicted. Enhanced glutamate clearance may reduce excitotoxicity associated with seizure activity.

Figure 489

Summary of multi-target pharmacology of phytocannabinoids relevant to epilepsy is presented. The polypharmacological profile of these compounds may explain their broad-spectrum anticonvulsant activity.

Figure 490

Vanilloid receptor (TRPV1) interactions with phytocannabinoid compounds are depicted in relation to seizure modulation. TRPV1 desensitization by CBD may contribute to its anticonvulsant properties.

Figure 491

Anandamide and 2-AG metabolic enzyme interactions with phytocannabinoids are illustrated. Inhibition of endocannabinoid degradation may enhance endogenous anticonvulsant tone.

Figure 492

Orphan receptor GPR55 modulation by phytocannabinoids is shown in the context of epilepsy. GPR55 antagonism by CBD represents a non-classical cannabinoid mechanism.

Figure 493

Voltage-gated calcium channel subtypes affected by phytocannabinoid compounds are depicted. T-type calcium channel inhibition is associated with absence seizure control.

Figure 494

Inflammatory mediator pathways modulated by phytocannabinoids in epileptic brain tissue are outlined. Neuroinflammation contributes to seizure generation and progression.

Figure 495

Oxidative stress pathways relevant to phytocannabinoid neuroprotection in epilepsy are shown. Antioxidant properties of CBD and other phytocannabinoids may reduce seizure-related damage.

Figure 496

Aquaporin channel interactions with phytocannabinoid treatment are depicted. Water homeostasis disruption contributes to seizure-associated cerebral edema.

Figure 497

Opioid receptor cross-talk with cannabinoid signaling in the context of seizure control is illustrated. Mu and kappa opioid receptors may modulate phytocannabinoid efficacy.

Figure 498

Glutamate transporter modulation by phytocannabinoids is depicted. Enhanced glutamate clearance may reduce excitotoxicity associated with seizure activity.

Figure 499

Summary of multi-target pharmacology of phytocannabinoids relevant to epilepsy is presented. The polypharmacological profile of these compounds may explain their broad-spectrum anticonvulsant activity.

Figure 500

Vanilloid receptor (TRPV1) interactions with phytocannabinoid compounds are depicted in relation to seizure modulation. TRPV1 desensitization by CBD may contribute to its anticonvulsant properties.

Figure 501

Anandamide and 2-AG metabolic enzyme interactions with phytocannabinoids are illustrated. Inhibition of endocannabinoid degradation may enhance endogenous anticonvulsant tone.

Figure 502

Orphan receptor GPR55 modulation by phytocannabinoids is shown in the context of epilepsy. GPR55 antagonism by CBD represents a non-classical cannabinoid mechanism.

Figure 503

Voltage-gated calcium channel subtypes affected by phytocannabinoid compounds are depicted. T-type calcium channel inhibition is associated with absence seizure control.

Figure 504

Inflammatory mediator pathways modulated by phytocannabinoids in epileptic brain tissue are outlined. Neuroinflammation contributes to seizure generation and progression.

Figure 505

Oxidative stress pathways relevant to phytocannabinoid neuroprotection in epilepsy are shown. Antioxidant properties of CBD and other phytocannabinoids may reduce seizure-related damage.

Figure 506

Aquaporin channel interactions with phytocannabinoid treatment are depicted. Water homeostasis disruption contributes to seizure-associated cerebral edema.

Figure 507

Opioid receptor cross-talk with cannabinoid signaling in the context of seizure control is illustrated. Mu and kappa opioid receptors may modulate phytocannabinoid efficacy.

Figure 508

Glutamate transporter modulation by phytocannabinoids is depicted. Enhanced glutamate clearance may reduce excitotoxicity associated with seizure activity.

Figure 509

Summary of multi-target pharmacology of phytocannabinoids relevant to epilepsy is presented. The polypharmacological profile of these compounds may explain their broad-spectrum anticonvulsant activity.

Figure 510

Vanilloid receptor (TRPV1) interactions with phytocannabinoid compounds are depicted in relation to seizure modulation. TRPV1 desensitization by CBD may contribute to its anticonvulsant properties.

Figure 511

Anandamide and 2-AG metabolic enzyme interactions with phytocannabinoids are illustrated. Inhibition of endocannabinoid degradation may enhance endogenous anticonvulsant tone.

Figure 512

Orphan receptor GPR55 modulation by phytocannabinoids is shown in the context of epilepsy. GPR55 antagonism by CBD represents a non-classical cannabinoid mechanism.

Figure 513

Voltage-gated calcium channel subtypes affected by phytocannabinoid compounds are depicted. T-type calcium channel inhibition is associated with absence seizure control.

Figure 514

Nine phytocannabinoid molecular structures with demonstrated anticonvulsant activity are presented, including THC, CBD, CBDV, CBC, CBN, and CBG. These compounds represent the key cannabis-derived molecules investigated for their potential roles in seizure suppression.

Figure 515

Oxidative stress pathways relevant to phytocannabinoid neuroprotection in epilepsy are shown. Antioxidant properties of CBD and other phytocannabinoids may reduce seizure-related damage.

Figure 516

Aquaporin channel interactions with phytocannabinoid treatment are depicted. Water homeostasis disruption contributes to seizure-associated cerebral edema.

Figure 517

Opioid receptor cross-talk with cannabinoid signaling in the context of seizure control is illustrated. Mu and kappa opioid receptors may modulate phytocannabinoid efficacy.